46 / 48
middle- aged and older men: a meta-analysis of
randomized, placebo-controlled trials. J Geront
A Biol Sci Med Sci 2005;60:1451-7.
41.
Bhasin S, Cunnigham GR, Hayes FJ,
Matsumoto AM, Snyder PJ, Swedloff RS, et al.
Testosterone therapy in men with androgen
deficiency syndromes: an Endocrine Society
clinical practice guideline. J Clin Endocrinol
Metab 2010; 95:2536-59.
42.
Wang C, Nieschlag E, Swerdloff R, Behre
HM, Hellstrom WJ, Gooren LJ et al.
Investigation, treatement, and monitoring of
late-onset hypogonadism in males: ISA, ISSAM,
EAU, EAA, and ASA recommendations. J
Androl 2009;30:1-9.
43.
Zitzmann M, Nieschlag E. Androgen
receptor gene CAG repeat length and body
mass index modulate the safety of long- term
intramuscular
testosterone
undecanoate
therapy in hypogonadal men. J Clin.
EndocrinolMetab 2007; 92:3844-53.
44.
Emmelot-Vonk MH, Verhaar HJ, Nakhai
Pour HR, Aleman A, Lock TM, Bosch JL, et al.
Effect of testosterone supplementation on
functional mobility, cognition, and other
parameters in older men: a randomized
controlled trial. JAMA 2008;299: 39-52
45.
Rhoden EL, Morgentaler A. Risks of
testosterone-replacement
therapy
and